
apr pm et
summari diversifi health care product compani focus nutrit diagnost gener
drug medic devic follow recent spin-off one divis
nm price-to-earnings oper ep
risk assess reflect abbott oper
competit market exposur rise price
pressur global market howev compani
rel strong posit key health care product
categori prospect brighten on-going
launch new medic product expans
fiscal year end dec ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
apr pm stock trade
see sale inclus st jude
medic stj aler rise
organ basi expect
revenu grow compris
devic sale grow mid- high-singl
digit diagnost sale mid-
high-singl digit pharmaceut
doubl digit nutrit low-
pharmaceut sale growth due
brand gener model emerg market
achiev double-digit growth
diagnost sale alin system
acceler europ like come
global market next year
januari complet
acquisit stj stj leader
cardiac neuromodul medic devic
sale combin
enabl becom leader
firm aler sale
make world leader point-of-car
medic optic unit johnson johnson
ep estim use
effect tax rate
acquisit divestitur
posit enabl establish
market-lead posit sever categori
also view divers product offer
geograph presenc posit growth
expect broadli across product
geographi addit stj
aler reposit portfolio
diagnost devic
largest segment expect
pursu sizeabl acquisit
compani focus dividend growth
debt paydown april paid
debt expect pay
anoth expect would
bring leverag net debt-to-ebitda
modest encourag recent
product launch alin system
freestyl libr alreadi
user grow
monthli pace
pressur failur integr stabil
aler weak execut new product
launch upcom pipelin
target base
slightli peer next
ep estim due robust
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview follow earli januari spin-off research-bas pharmaceut
oper form share new compani call abbott busi larg
concentr nutrit product diagnost establish pharmaceut brand gener
medic devic divers oper larg result strateg acquisit made
year well intern program abbott command lead market posit immunoassay
blood screen product coronari metal drug-elut stent lasik devic pediatr
nutrit compani world-wide leader adult nutrit
nutrit product fall -base ross product abbott nutrit intern product
includ lead infant formula sold similac isomil name well adult nutrit
ensur prosur patient special dietari need includ cancer diabet patient
compani continu establish pharmaceut busi compris brand gener
sold emerg market develop market brand gener typic command higher margin
convent gener especi emerg market brand label afford sens
qualiti reliabl unbrand drug growth strategi busi compris effort
increas breadth product offer launch new improv formul regist
offer wide rang test diagnost system blood bank hospit lab princip
product includ screen test hepat hiv infecti diseas cancer clinic
chemistri system diagnost instrument chemic reagent immunoassay test kit hematolog
system reagent pregnanc test
abbott vascular market coronari carotid stent cathet guid wire product use
surgic closur princip product new xienc drug-elut stent de present
lead product domest de market expand launch new xienc
xpedit stent line japan increas global market penetr newer product
mitraclip mitral valv repair system absorb bioresorb vascular scaffold
product includ diabet care item precis freestyl line hand-held glucos
monitor diabet patient well data manag point-of-car system insulin pump
syring diabet glucerna shake nutrit bar tailor diabet also offer
juli sold non-u develop market specialti brand gener busi
nv billion august acquir optimedica ophthalm devic maker million
medic devic maker million februari abbott acquir
advanc medic optic amo billion amo leader ophthalm care posit
lasik surgic devic posit cataract surgic product slot contact len
care product februari sold amo johnson johnson billion januari
complet acquisit st jude medic billion stj leader cardiac
neuromodul medic devic sale billion believ combin enabl
becom leader cardiovascular care octob acquir aler billion aler
lead point-of-car diagnost firm billion sale
execut vice-president financ
chairman board
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
neutral sinc april technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
procedur inpati
includ increas global demand
qualiti health care age popul
rise outlay lead steadi flow
new diagnost therapeut product
 health equip
 composit index year
date april health
declin composit index
fundament outlook health care
equip sub-industri next month
posit continu view mani product
categori histor recession-resist
expect continu grow growth
procedur rate area view
non-elect cardiac rhythm
manag intervent cardiolog
orthoped steadili improv
see continu recoveri
medic devic tax requir
healthcar reform law went effect
januari temporarili suspend
januari
congress pass stopgap measur includ
suspend medic devic tax anoth
two year tax
slate becom effect januari
decemb congress pass tax cut
job act includ repeal
individu mandat compon
afford act requir
peopl health insur pay fine
effect januari believ repeal
individu mandat result fewer
insur peopl neg impact
equip sub-industri fewer insur
patient would like lead fewer procedur
anticip hospit
largest buyer medic equip would also
advers impact could
pressur sub-industri
expect revenu rise constant
currenc mid- upper-singl digit pace
aid new product expans emerg
market case acquisit
still expect extend replac cycl
 hospit area price
pressur lower demand certain product
categori affect sale growth also think
 hospit becom cautiou
regard capit budget amid shift
base index
five-year market price perform apr
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
termin origin deal alr encount sever advers event includ
govern subpoena relat oversea sale practic alr delay file
annual report due time revenu recognit one alr subsidiari
also lost medicar bill privileg appeal compani expect
deal complet /jeffrey loo cfa
laboratori keep target in-lin
peer ep estim set ep ep
vs estim sale rose sale
largest unit nutrit fell challeng china see continu
throughout diagnost rose establish pharma medic
devic guid pro-forma sale growth inclus st jude
medic exclud pend sale abbott medic optic mid-singl
digit ep rang accret st
laboratori file complaint delawar court
chanceri seek termin deal acquir aler alr nr
provid point-of-car diagnost expect take step
detail relat oversea sale practic alr subsequ delay file
annual report due time revenu recognit sever oversea
market howev alr said fulli compliant merger term
expect deal complet view unlik /jeffrey loo
et cfra keep hold opinion share abbott laboratori
keep target in-lin peer
forward ep estim ep vs
ahead estim lower ep estim
see challeng china led slowdown nutrit sale
continu throughout although china account
sale import market driver growth separ
st jude medic deal remain on-track close year-end aler
deal still question amid regulatori investig /jeffrey loo cfa
analyst research note compani news
keep target above-p
next ep estim due robust pipelin
ep estim remain unchang respect
ep vs ep higher estim
pharmaceut medic devic total sale grew organ
line expect organ growth
diabet care busi grew driven recent
launch freestyl libr user global monthli growth
diabet care could import growth driver year come
addit cadenc new product launch continu invest
research develop million vs
persuad us continu see organ growth exce
growth experienc recent year /kevin huang
et cfra rais opinion share abbott laboratori
buy hold rais target
peer ep estim set
ep vs ahead estim sale aid
acquisit rose encourag broad-bas product
geograph growth medic devic establish pharmaceut
diagnost nutrit rebound grew
pediatr nutrit sale grew china follow soft regulatori
chang believ well posit continu broad-bas growth
rais target line peer
forward ep estim ep vs
line estim rais ep estim
sale aid st jude acquisit rose oper basi
nutrit sale rose oversea sale rose rebound
recent declin china sale improv sequenti diagnost sale rose
rose encourag broad-bas
see acceler diagnost follow aler deal /jeffrey loo
et cfra keep hold opinion share abbott laboratori
rais target in-line-with-p
forward ep rais ep estim
ep vs estim sale
inclus st jude medic rose compar basi nutrit
sale fell oversea rose overal diagnost rose
pharmaceut medic devic nutrit sale china
remain challeng pend regulatori chang see solid sale
devic believ st jude integr proceed well /jeffrey loo
keep target in-lin peer
ep estim ep vs ahead
estim sale st jude medic rose nutrit sale remain
challeng fall declin china infant formula see
continu challeng pend new regul diagnost rose
strong growth core laboratori point-of-car see diagnost
growth driver aler acquisit back track establish
pharmaceut rose medic devic rose /jeffrey loo cfa
et cfra keep hold opinion share abbott laboratori
aler inc alr nr agre lower merger price
acquir alr
firm drop lawsuit tri
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
